Global Myelofibrosis Therapeutics Market 2018-2022
SKU ID : TNV-13753953 | Publishing Date : 21-Dec-2018 | No. of pages : 106
Detailed TOC of Global Myelofibrosis Therapeutics Market 2018-2022
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT
• Segmentation by type of treatment
• Comparison by type of treatment
• Drug therapy – Market size and forecast 2017-2022
• Blood transfusion – Market size and forecast 2017-2022
• HSCT – Market size and forecast 2017-2022
• Androgen Therapy – Market size and forecast 2017-2022
• Market opportunity by type of treatment
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• HSCT is the only curative option for myelofibrosis
• High off-label prescription including hydroxyurea, Immunomodulators, and steroids
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• CELGENE
• Incyte
• Novartis
PART 16: APPENDIX
• List of abbreviations
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Type of treatment – Market share 2017-2022 (%)
Exhibit 20: Comparison by type of treatment
Exhibit 21: Drug therapy – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
Exhibit 23: Drug therapy – Year-over-year growth 2018-2022 (%)
Exhibit 24: Blood transfusion – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Blood transfusion – Year-over-year growth 2018-2022 (%)
Exhibit 26: HSCT – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: HSCT – Year-over-year growth 2018-2022 (%)
Exhibit 28: Androgen therapy – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Androgen Therapy – Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by type of treatment
Exhibit 31: Customer landscape
Exhibit 32: Global – Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in EMEA
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb – Overview
Exhibit 49: Bristol-Myers Squibb – Business segments
Exhibit 50: Bristol-Myers Squibb – Organizational developments
Exhibit 51: Bristol-Myers Squibb – Geographic focus
Exhibit 52: Bristol-Myers Squibb – Key offerings
Exhibit 53: Bristol-Myers Squibb – Key customers
Exhibit 54: CELGENE – Overview
Exhibit 55: CELGENE – Business segments
Exhibit 56: CELGENE – Organizational developments
Exhibit 57: CELGENE – Geographic focus
Exhibit 58: CELGENE – Key offerings
Exhibit 59: CELGENE – Key customers
Exhibit 60: Incyte – Overview
Exhibit 61: Incyte – Business segments
Exhibit 62: Incyte – Organizational developments
Exhibit 63: Incyte – Geographic focus
Exhibit 64: Incyte – Key offerings
Exhibit 65: Incyte – Key customers
Exhibit 66: Novartis – Overview
Exhibit 67: Novartis – Business segments
Exhibit 68: Novartis – Organizational developments
Exhibit 69: Novartis – Geographic focus
Exhibit 70: Novartis – Segment focus
Exhibit 71: Novartis – Key offerings
Exhibit 72: Novartis – Key customers
Keyplayers in Global Myelofibrosis Therapeutics Market 2018-2022
Bristol-Myers SquibbCELGENE
Incyte
Novartis